BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18378535)

  • 1. Concept and clinical evaluation of carrier-mediated anticancer agents.
    Zamboni WC
    Oncologist; 2008 Mar; 13(3):248-60. PubMed ID: 18378535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of anticancer drugs.
    Zee-Cheng RK; Cheng CC
    Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.
    Wong HL; Bendayan R; Rauth AM; Li Y; Wu XY
    Adv Drug Deliv Rev; 2007 Jul; 59(6):491-504. PubMed ID: 17532091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.
    Caron WP; Song G; Kumar P; Rawal S; Zamboni WC
    Clin Pharmacol Ther; 2012 May; 91(5):802-12. PubMed ID: 22472987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
    Petschauer JS; Madden AJ; Kirschbrown WP; Song G; Zamboni WC
    Nanomedicine (Lond); 2015 Feb; 10(3):447-63. PubMed ID: 25707978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticles for delivery of chemotherapeutic agents to tumors.
    Vijayaraghavalu S; Raghavan D; Labhasetwar V
    Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
    Lucas AT; Madden AJ; Zamboni WC
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1419-33. PubMed ID: 26173794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal nanomedicines.
    Fenske DB; Cullis PR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):25-44. PubMed ID: 18095927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles for drug delivery in cancer treatment.
    Haley B; Frenkel E
    Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y; Sadhukha T; Ma L; Panyam J
    J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
    Hamad I; Moghimi SM
    Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
    Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
    Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and pharmacokinetics of lipid nanoparticles of a chemically sensitive nitrogen mustard derivative: Chlorambucil.
    Sharma P; Ganta S; Denny WA; Garg S
    Int J Pharm; 2009 Feb; 367(1-2):187-94. PubMed ID: 18930127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle therapeutics: an emerging treatment modality for cancer.
    Davis ME; Chen ZG; Shin DM
    Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro.
    Khdair A; Handa H; Mao G; Panyam J
    Eur J Pharm Biopharm; 2009 Feb; 71(2):214-22. PubMed ID: 18796331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
    Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
    Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.
    Acharya S; Dilnawaz F; Sahoo SK
    Biomaterials; 2009 Oct; 30(29):5737-50. PubMed ID: 19631377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein nanoparticles as drug carriers in clinical medicine.
    Hawkins MJ; Soon-Shiong P; Desai N
    Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.